Carisma Therapeutics (CARM) to Release Quarterly Earnings on Monday

Carisma Therapeutics (NASDAQ:CARM) is projected to announce its earnings results before the market opens on Monday, March 31st. Analysts expect the company to announce earnings of ($0.17) per share and revenue of $5.42 million for the quarter.

Carisma Therapeutics Stock Performance

Shares of NASDAQ CARM opened at $0.33 on Friday. The company has a quick ratio of 3.23, a current ratio of 3.23 and a debt-to-equity ratio of 1.39. The firm’s 50-day moving average price is $0.44 and its two-hundred day moving average price is $0.67. The stock has a market capitalization of $13.78 million, a P/E ratio of -0.21 and a beta of 1.55. Carisma Therapeutics has a 52-week low of $0.33 and a 52-week high of $2.30.

Analyst Ratings Changes

A number of research firms have issued reports on CARM. Baird R W cut Carisma Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, December 12th. HC Wainwright reaffirmed a “neutral” rating on shares of Carisma Therapeutics in a research note on Monday, December 16th. D. Boral Capital reissued a “buy” rating and issued a $12.00 price objective on shares of Carisma Therapeutics in a research note on Monday, January 13th. Robert W. Baird downgraded shares of Carisma Therapeutics from an “outperform” rating to a “neutral” rating and cut their price target for the company from $10.00 to $1.00 in a report on Thursday, December 12th. Finally, BTIG Research downgraded shares of Carisma Therapeutics from a “buy” rating to a “neutral” rating in a report on Tuesday, December 10th. Five investment analysts have rated the stock with a hold rating, one has issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Carisma Therapeutics has an average rating of “Hold” and an average price target of $4.94.

About Carisma Therapeutics

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.